Tumour necrosis factor blockade mediates altered serotonin transporter availability in rheumatoid arthritis: a clinical, proof-of-concept study

Ann Rheum Dis. 2010 Jun;69(6):1251-2. doi: 10.1136/ard.2009.107912. Epub 2010 Apr 6.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adalimumab
  • Antibodies, Monoclonal / therapeutic use
  • Antibodies, Monoclonal, Humanized
  • Antirheumatic Agents / therapeutic use
  • Arthritis, Rheumatoid / drug therapy*
  • Arthritis, Rheumatoid / metabolism
  • Brain / metabolism
  • Humans
  • Serotonin Plasma Membrane Transport Proteins / metabolism*
  • Tumor Necrosis Factor-alpha / antagonists & inhibitors*

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Antirheumatic Agents
  • Serotonin Plasma Membrane Transport Proteins
  • Tumor Necrosis Factor-alpha
  • Adalimumab